SURVIVAL OUTCOMES IN FAMILIAL PANCREATIC CANCER.

Pancreas ◽  
2004 ◽  
Vol 29 (4) ◽  
pp. 348
Author(s):  
N. Omer ◽  
K. Boucher ◽  
J. DiSario
Cancers ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1612
Author(s):  
Julie Earl ◽  
Emma Barreto ◽  
María E. Castillo ◽  
Raquel Fuentes ◽  
Mercedes Rodríguez-Garrote ◽  
...  

Pancreatic ductal adenocarcinoma (PDAC) presents many challenges in the clinic and there are many areas for improvement in diagnostics and patient management. The five-year survival rate is around 7.2% as the majority of patients present with advanced disease at diagnosis that is treatment resistant. Approximately 10–15% of PDAC cases have a hereditary basis or Familial Pancreatic Cancer (FPC). Here we demonstrate the use of circulating free DNA (cfDNA) in plasma as a prognostic biomarker in PDAC. The levels of cfDNA correlated with disease status, disease stage, and overall survival. Furthermore, we show for the first time via BEAMing that the majority of hereditary or familial PDAC cases (around 84%) are negative for a KRAS somatic mutation. In addition, KRAS mutation negative cases harbor somatic mutations in potentially druggable genes such as KIT, PDGFR, MET, BRAF, and PIK3CA that could be exploited in the clinic. Finally, familial or hereditary cases have a longer overall survival compared to sporadic cases (10.2 vs. 21.7 months, respectively). Currently, all patients are treated the same in the clinic with cytotoxic agents, although here we demonstrate that there are different subtypes of tumors at the genetic level that could pave the way to personalized treatment.


2015 ◽  
Vol 6 (2) ◽  
pp. 166-175 ◽  
Author(s):  
Nicholas J. Roberts ◽  
Alexis L. Norris ◽  
Gloria M. Petersen ◽  
Melissa L. Bondy ◽  
Randall Brand ◽  
...  

Pancreatology ◽  
2017 ◽  
Vol 17 (3) ◽  
pp. S68
Author(s):  
Andrea Sheel ◽  
Sara Harrison ◽  
Ioannis Sarantitis ◽  
James Nicholson ◽  
Christopher Halloran ◽  
...  

2001 ◽  
Vol 3 (2) ◽  
pp. 121-128 ◽  
Author(s):  
Henry T. Lynch ◽  
Randall E. Brand ◽  
Carolyn A. Deters ◽  
Ramon M. Fusaro

2003 ◽  
Vol 124 (5) ◽  
pp. 1292-1299 ◽  
Author(s):  
Stephen J Rulyak ◽  
Albert B Lowenfels ◽  
Patrick Maisonneuve ◽  
Teresa A Brentnall

2004 ◽  
Vol 110 (6) ◽  
pp. 902-906 ◽  
Author(s):  
Detlef K. Bartsch ◽  
Ralf Kress ◽  
Mercedes Sina-Frey ◽  
Robert Grützmann ◽  
Berthold Gerdes ◽  
...  

2002 ◽  
pp. 101-107
Author(s):  
D.K. Bartsch ◽  
M. Sina-Frey ◽  
A. Ziegler ◽  
S.A. Hahn ◽  
E. Przypadlo ◽  
...  

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Kodai Abe ◽  
Arisa Ueki ◽  
Yusaku Urakawa ◽  
Minoru Kitago ◽  
Tomoko Yoshihama ◽  
...  

Abstract Background Family history is one of the risk factors for pancreatic cancer. It is suggested that patients with pancreatic cancer who have a familial history harbor germline pathogenic variants of BRCA1 and/or BRCA2 (BRCA1/2), PALB2, or ATM. Recently, some germline variants of familial pancreatic cancers (FPCs), including PALB2, have been detected. Several countries, including Japan, perform screening workups and genetic analysis for pancreatic cancers. We have been carrying out active surveillance for FPC through epidemiological surveys, imaging analyses, and genetic analysis. Case presentation Here, we present the case of a female patient harboring pathogenic variants of PALB2 and NBN, with a family history of multiple pancreatic cancer in her younger brother, her aunt, and her father. Moreover, her father harbored a PALB2 pathogenic variant and her daughter harbored the same NBN pathogenic variant. Given the PALB2 and NBN variants, we designed surveillance strategies for the pancreas, breast, and ovary. Conclusions Further studies are required to develop strategies for managing FPCs to facilitate prompt diagnosis before their progression.


Sign in / Sign up

Export Citation Format

Share Document